RPTP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RPTP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-05), Raptor Pharmaceutical's share price is $9.00. Raptor Pharmaceutical's Book Value per Share for the quarter that ended in Jun. 2016 was $0.79. Hence, Raptor Pharmaceutical's PB Ratio of today is 11.38.
The historical rank and industry rank for Raptor Pharmaceutical's PB Ratio or its related term are showing as below:
The historical data trend for Raptor Pharmaceutical's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raptor Pharmaceutical Annual Data | |||||||||||||||||||||
Trend | Dec06 | Dec07 | Dec08 | Aug09 | Aug10 | Aug11 | Aug12 | Dec13 | Dec14 | Dec15 | |||||||||||
PB Ratio | Get a 7-Day Free Trial | - | 9.40 | 28.06 | 14.80 | 3.78 |
Raptor Pharmaceutical Quarterly Data | ||||||||||||||||||||
Aug11 | Nov11 | Feb12 | May12 | Aug12 | Nov12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | |
PB Ratio | Get a 7-Day Free Trial | 10.57 | 4.46 | 3.78 | 5.01 | 6.79 |
For the Biotechnology subindustry, Raptor Pharmaceutical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Raptor Pharmaceutical's PB Ratio distribution charts can be found below:
* The bar in red indicates where Raptor Pharmaceutical's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Raptor Pharmaceutical's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Jun. 2016) |
= | 9.00 | / | 0.791 | |
= | 11.38 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Raptor Pharmaceutical (NAS:RPTP) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Raptor Pharmaceutical's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Raymond Anderson | director | C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Krishna R Polu | officer: Chief Medical Officer | C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949 |
Michael P Smith | officer: Chief Financial Officer | 887 GREAT NORTHERN WAY VANCOUVER A1 V5T 4T5 |
Suzanne Louise Bruhn | director | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746 |
Georges Gemayel | director | 550 HILLS DRIVE, BEDMINSTER NJ 07921 |
Llew Keltner | director | 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949 |
Christopher M Starr | director | C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
David Happel | officer: Chief Commercial Officer | 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949 |
Julie Smith | director, officer: President and CEO | C/O RAPTOR PHARMACEUTICAL CORP, 9 COMMERCIAL BLVD, SUITE 200, NOVATO CA 94949 |
Anthony Gregg Lapointe | director | PO BOX 83216, GAITHERSBURG MD 20883-3216 |
Erich Sager | director | 9 COMMERCIAL BLVD., SUITE 200, NOVATO CA 94949 |
Georgia Erbez | officer: Chief Financial Officer | 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Vijay B Samant | director | 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121 |
Timothy P Walbert | director | 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062 |
Patrice Rioux | other: CMO, Raptor Therapeutics | C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.